



Bile Acid Synthesis Disorders
Atypical Bile Acid Test

REPORT TO

Physician Name (print):
Clinic/Institution Name:
Address:
City: State: Zip:
Phone: ()
Email:
NPI #

FAX NUMBER FOR RESULTS:
The Laboratory DOES NOT bill patients or insurance companies
This is a program supported by Mirum Pharmaceuticals, Inc.

SAMPLE/SPECIMEN INFORMATION

Sample Type: Urine (1 – 25 mL)
Sample Collection Date (MM/DD/YYYY): / /

Internal Use only:
Received date:
FL#:
FAB#:

SHIPPING INFORMATION

- Shipment Requirements:
• US SHIPMENTS ONLY
• SHIP FROZEN
- ON ICE PACKS OR
- DRY ICE
• OVERNIGHT EXPRESS
- NO WEEKEND DELIVERY

Ship to:
Clinical Mass Spectrometry Facility, MLC 7019
Department of Pathology and Laboratory Medicine
Cincinnati Children's Hospital Medical Center
3333 Burnet Avenue
Cincinnati, OH 45229-3099
Phone: (513) 636-4203 Fax: (513) 803-5014

PATIENT INFORMATION

THE FOLLOWING INFORMATION IS REQUIRED FOR EACH SAMPLE
Patient Name: Last First MI
Date of Birth (MM/DD/YYYY): / /
Patient ID/Med Rec #:
Address:
City: State: Zip:
Preferred Phone: ()
Other # Where Patient can be Reached: ()
Sex: Male Female Unknown
Parent Name (if patient is minor):
Spouse:

- Ethnicity of Patient (check all that apply):
African American Asian Caucasian NW European E Indian
Hispanic Ashkenazi Jewish Sephardic Jewish Mediterranean
Native American NativeHawaiian/Other Pacific Islander Other

Because Ursodeoxycholic acid can mask detection of bile acid synthetic disorders, the patient should be temporarily taken off URSO® or ACTIGALL® (ursodiol) for 5 DAYS before sample collection.

List Medications:
Is the patient currently on URSO® or ACTIGALL® (ursodiol), or has been within the past month? If yes, please provide the DATES of medication:

Clinical History/Preliminary Diagnosis:

ICD-10:

CRITERIA FOR FREE TESTING

Please check boxes and attest:

- Patient must meet one of the following:
Pathogenic Variant or VOUS from a genetic test on one of the following genes:
- HSD3B7, AKR1D1, AMACR, CYP7B1
Negative result on genetic test but patient has GGT≤150 IU/L and direct bilirubin >1 mg/dL

I hereby attest that the patient meets the attached criteria and is a candidate for the Atypical Bile Acid Test via FAB-MS. I understand the diagnostic testing services offered under this program are directional in nature and that they do not eliminate the need for additional medical management or replace any existing diagnostic methods. I further understand that neither Mirum Pharmaceuticals, Inc. nor Cincinnati Children's Hospital makes any claims as to the usefulness of this test.

Signature: